Bristol-Myers Squibb Co (BMY)
44.03
-0.08
(-0.18%)
USD |
NYSE |
May 17, 16:00
44.00
-0.03
(-0.07%)
After-Hours: 20:00
Bristol-Myers Squibb SG&A Expense (TTM): 8.377B for March 31, 2024
SG&A Expense (TTM) Chart
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 8.377B |
| December 31, 2023 | 7.772B |
| September 30, 2023 | 7.965B |
| June 30, 2023 | 7.892B |
| March 31, 2023 | 7.745B |
| December 31, 2022 | 7.814B |
| September 30, 2022 | 7.902B |
| June 30, 2022 | 7.76B |
| March 31, 2022 | 7.855B |
| December 31, 2021 | 7.69B |
| September 30, 2021 | 8.057B |
| June 30, 2021 | 7.975B |
| March 31, 2021 | 7.721B |
| December 31, 2020 | 7.661B |
| September 30, 2020 | 6.674B |
| June 30, 2020 | 6.023B |
| March 31, 2020 | 5.471B |
| December 31, 2019 | 4.871B |
| September 30, 2019 | 4.473B |
| June 30, 2019 | 4.522B |
| March 31, 2019 | 4.577B |
| December 31, 2018 | 4.551B |
| September 30, 2018 | 4.531B |
| June 30, 2018 | 4.59B |
| March 31, 2018 | 4.646B |
| Date | Value |
|---|---|
| December 31, 2017 | 4.751B |
| September 30, 2017 | 4.898B |
| June 30, 2017 | 4.898B |
| March 31, 2017 | 4.974B |
| December 31, 2016 | 4.979B |
| September 30, 2016 | 5.066B |
| June 30, 2016 | 5.127B |
| March 31, 2016 | 5.035B |
| December 31, 2015 | 5.001B |
| September 30, 2015 | 5.555B |
| June 30, 2015 | 5.559B |
| March 31, 2015 | 5.571B |
| December 31, 2014 | 5.699B |
| September 30, 2014 | 4.944B |
| June 30, 2014 | 4.927B |
| March 31, 2014 | 5.105B |
| December 31, 2013 | 5.104B |
| September 30, 2013 | 5.265B |
| June 30, 2013 | 5.295B |
| March 31, 2013 | 5.162B |
| December 31, 2012 | 5.175B |
| September 30, 2012 | 5.176B |
| June 30, 2012 | 5.159B |
| March 31, 2012 | 5.224B |
| December 31, 2011 | 5.17B |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (TTM) Range, Past 5 Years
4.473B
Minimum
Sep 2019
8.377B
Maximum
Mar 2024
7.111B
Average
7.752B
Median
SG&A Expense (TTM) Benchmarks
| Amgen Inc | 6.729B |
| Gilead Sciences Inc | 6.147B |
| Johnson & Johnson | 21.93B |
| Eli Lilly and Co | 6.912B |
| 2seventy bio Inc | 61.35M |